Lung cancer staging: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
Line 2: Line 2:


{{CMG}}; '''Associate Editor(s)-In-Chief:''' Kim-Son H. Nguyen, M.D., M.P.A., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, {{CZ}}; '''Assistant Editor(s)-In-Chief:''' [[User:Michael Maddaleni|Michael Maddaleni, B.S.]]
{{CMG}}; '''Associate Editor(s)-In-Chief:''' Kim-Son H. Nguyen, M.D., M.P.A., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, {{CZ}}; '''Assistant Editor(s)-In-Chief:''' [[User:Michael Maddaleni|Michael Maddaleni, B.S.]]


==Overview==
==Overview==
Line 30: Line 29:
:[[EUS-FNA]] (esophogeal endoscopic ultrasound guided fine needle aspiration).</br>
:[[EUS-FNA]] (esophogeal endoscopic ultrasound guided fine needle aspiration).</br>


==Staging Classifications==
==TNM Classification of Lung Cancer==
===Primary tumor===
===T: Primary Tumor===
*Tis - Carcinoma in situ
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
*TX - Positive malignant cytologic findings, no lesion observed
|-
*T1 - Diameter of 3 cm or smaller and surrounded by lung or visceral pleura or endobronchial tumor distal to the lobar bronchus
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''T'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''Description'''
*T2 - Diameter greater than 3 cm ; extension to the visceral pleura, [[atelectasis]], or obstructive pneumopathy involving less than 1 lung; lobar endobronchial tumor; or tumor of a main bronchus more than 2 cm from the carina
|-
*T3 - Tumor at the apex; total atelectasis of 1 lung; endobronchial tumor of main bronchus within 2 cm of the carina but not invading it; or tumor of any size with direct extension to the adjacent structures (i.e. chest wall mediastinal pleura, diaphragm, pericardium parietal layer).
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |TX || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Primary tumor cannot be assessed.<br> OR <br>Tumor is demonstrated by the presence of malignant cells in bronchial washings or [[sputum]], but is not visualized by imaging or [[bronchoscopy]].
*T4 - Invasion of the mediastinal organs (i.e esophagus, trachea, carina, great vessels, heart), obstruction of the superior vena cava; involvement of a vertebral body; recurrent nerve involvement; malignant [[pleural effusion]], malignant [[pericardial effusion]]; or satellite pulmonary nodules within the same lobe as the primary tumor
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | T0 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is no evidence of primary tumor.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Tis ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Carcinoma in situ
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T1 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |The tumor has the following characteristics: <br> The greatest dimension is <3 cm <br> AND <br>The tumor is surrounded by lung or [[visceral pleura]]<br> AND <br>The tumor does not extend to the main bronchus as demonstrated by the absence of bronchoscopic evidence of invasion more proximal than the lobar bronchus.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T2 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |The tumor has the following characteristics:<br>
The greatest dimension is >3cm
<br> OR <br>
The tumor involves the main bronchus, 2 cm or more distal to the [[carina]].
<br> OR <br>
The tumor invades the [[visceral pleura]].
<br> OR <br>
There is evidence of [[atelectasis]] or obstructive [[pneumonitis]] that extends to the hilar region without the involvement of the entire lung.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T3 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |The tumor is of any size AND it directly invades any of the following: [[chest wall]] (including superior sulcus tumors), [[diaphragm]], mediastinal pleura, parietal [[pericardium]].
<br> OR <br>The tumor is localized in the main bronchus at a distance less than 2 cm distal to the [[carina]] but without the involvement of the [[carina]].
<br> OR <br>There is evidence of associated [[atelectasis]] or obstructive [[pneumonitis]] of the entire lung.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T4 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |The tumor is of any size that invades any of the following: [[mediastinum]], [[heart]], great vessels, [[trachea]], [[esophagus]], [[vertebral body]], [[carina]]<br> OR <br>There is/are separate tumor nodule(s) in the same lobe. <br> OR <br>
The tumor is associated with malignant [[pleural effusion]].
|}


===Regional lymph node involvement===
===N:Regional Lymph Nodes===
*N0 - No lymph nodes involved
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
*N1 - Ipsilateral hilar nodal involvement
|-
*N2 - Ipsilateral mediastinal involvement
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''T'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''Description'''
*N3 - Contralateral mediastinal or hilar nodal involvement or any scalene or supraclavicular nodal involvement
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |NX ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |the regional [[lymph node]]s cannot be assessed.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N0 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is no evidence of regional lymph node metastasis.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N1 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is [[metastasis]] in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N2 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is [[metastasis]] in ipsilateral mediastinal and/or subcarinal lymph node(s).
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N3 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is [[metastasis]] in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).
|}


===Metastatic involvement===
===M: Distant Metastasis===
*M0 - No metastases
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
*M1 - Metastases present
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''T'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''Description'''
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |MX ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Distant metastasis cannot be assessed.
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is no evidence of distant [[metastasis]].
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M1 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |There is evidence of [[distant]] metastasis which includes the presence of separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).
|}


===Stage groupings of Lung Cancer===
==Classification of Lung Cancer by Staging==
* IA - T1N0M0
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
* IB - T2N0M0
|-
* IIA - T1N1M0
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''Stage'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''T'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''N'''||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align=center |'''M'''
* IIB - T2N1M0 or T3N0M0
|-
* IIIA - T1-3N2M0 or T3N1M0
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Occult carcinoma''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |TX|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N0|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
* IIIB - Any T4 or any N3M0
|-
* IV - Any M1
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage 0''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Tis ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N0 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N1 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIB''' ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIIA''' ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T1, T2|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N2 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIIA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T3|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N1, N2 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIIB''' ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Any T|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |N3 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IIIB'''||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |T4 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Any N ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M0
|-
|style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |'''Stage IV'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Any T ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |Any N ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |M1
|}


==References==
==References==

Revision as of 19:51, 9 June 2014

Lung cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lung cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lung cancer staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lung cancer staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lung cancer staging

CDC on Lung cancer staging

Lung cancer staging in the news

Blogs on Lung cancer staging

Directions to Hospitals Treating Lung cancer

Risk calculators and risk factors for Lung cancer staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Kim-Son H. Nguyen, M.D., M.P.A., Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, Cafer Zorkun, M.D., Ph.D. [2]; Assistant Editor(s)-In-Chief: Michael Maddaleni, B.S.

Overview

Lung cancer staging is an assessment of the degree of spread of the cancer from its original source. It is an important factor affecting the prognosis and potential treatment of lung cancer.

Non-small cell lung carcinoma is staged from IA ("one A", best prognosis) to IV ("four", worst prognosis).[1] Small cell lung carcinoma is classified as limited stage if it is confined to one half of the chest and within the scope of a single radiotherapy field. Otherwise it is extensive stage.[2]

Procedures

There are currently multiple different procedures available to stage lung cancer. They can be broken down into two over-arching categories, invasive and minimally invasive.

The invasive procedures are:

EUS-NA (esophageal endoscopic ultrasound with needle aspiration)
TBNA (transbronchial needle aspiration)
EBUS-NA (endobronchial ultrasound with needle aspiration)
TTNA (transthoracic needle aspiration)
VATS staging (video assisted thoracic surgery) aka thoracoscopy.
Extended cervical mediastinoscopy
Chamberlain procedure

The minimally invasive procedures are:

EBUS-FNA (endobronchial ultrasound guided fine needle aspiration).
EUS-FNA (esophogeal endoscopic ultrasound guided fine needle aspiration).

TNM Classification of Lung Cancer

T: Primary Tumor

T Description
TX Primary tumor cannot be assessed.
OR
Tumor is demonstrated by the presence of malignant cells in bronchial washings or sputum, but is not visualized by imaging or bronchoscopy.
T0 There is no evidence of primary tumor.
Tis Carcinoma in situ
T1 The tumor has the following characteristics:
The greatest dimension is <3 cm
AND
The tumor is surrounded by lung or visceral pleura
AND
The tumor does not extend to the main bronchus as demonstrated by the absence of bronchoscopic evidence of invasion more proximal than the lobar bronchus.
T2 The tumor has the following characteristics:

The greatest dimension is >3cm
OR
The tumor involves the main bronchus, 2 cm or more distal to the carina.
OR
The tumor invades the visceral pleura.
OR
There is evidence of atelectasis or obstructive pneumonitis that extends to the hilar region without the involvement of the entire lung.

T3 The tumor is of any size AND it directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium.


OR
The tumor is localized in the main bronchus at a distance less than 2 cm distal to the carina but without the involvement of the carina.
OR
There is evidence of associated atelectasis or obstructive pneumonitis of the entire lung.

T4 The tumor is of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina
OR
There is/are separate tumor nodule(s) in the same lobe.
OR

The tumor is associated with malignant pleural effusion.

N:Regional Lymph Nodes

T Description
NX the regional lymph nodes cannot be assessed.
N0 There is no evidence of regional lymph node metastasis.
N1 There is metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension.
N2 There is metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).
N3 There is metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).

M: Distant Metastasis

T Description
MX Distant metastasis cannot be assessed.
M0 There is no evidence of distant metastasis.
M1 There is evidence of distant metastasis which includes the presence of separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).

Classification of Lung Cancer by Staging

Stage T N M
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T1 N1 M0
Stage IIB T2 N1 M0
Stage IIB T3 N0 M0
Stage IIIA T1, T2 N2 M0
Stage IIIA T3 N1, N2 M0
Stage IIIB Any T N3 M0
Stage IIIB T4 Any N M0
Stage IV Any T Any N M1

References

  1. Mountain, CF (2003). A Handbook for Staging, Imaging, and Lymph Node Classification. Charles P Young Company. Retrieved 2007-09-01. Unknown parameter |coauthors= ignored (help)
  2. Collins, LG (Jan 2007). "Lung cancer: diagnosis and management". American Family Physician. American Academy of Family Physicians. 75 (1): 56–63. PMID 17225705. Retrieved 2007-08-10. Unknown parameter |coauthors= ignored (help)

Template:Tumors


Template:WikiDoc Sources